TVA Medical

TVA Medical is a medical device company focused on minimally invasive vascular access technologies for patients with chronic kidney disease and end-stage renal disease requiring hemodialysis. Its lead product, the everlinQ endoAVF System, was designed to create an endovascular arteriovenous fistula using catheter-based magnetic alignment and radiofrequency energy rather than open surgery. The company was acquired by BD in July 2018, shortly after FDA De Novo authorization for everlinQ, and its technology became part of BD's chronic kidney disease and peripheral intervention portfolio. TVA Medical was backed by healthcare and strategic investors including Santé Ventures, S3 Ventures, TriStar Health Partners, Baxter Ventures, and Boston Scientific Ventures. The company appears to have operated primarily from Austin, Texas.